NADPH Oxidase Polymorphisms in Obstructive Sleep Apnea Syndrome (OSAS)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Obstructive Sleep Apnea (OSA) is associated with increased oxidative stress. The major sources of Reactive Oxygen Species (ROS) in the vasculature are the NADPH oxidases. Several polymorphisms related to NADPH oxidase expression or NADPH oxidase activity has been identified. The investigators are going to compare the distribution of the allelic frequencies of A-930G and C242T polymorphisms and their possible relationship with the levels of 8-isoprostanes as a marker of oxidative stress in patients with OSA and in a control group without OSA.
| Condition |
|---|
|
Sleep Apnea Syndrome Oxidative Stress Single Nucleotide Polymorphism |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Cross-Sectional |
| Official Title: | NADPH Oxidase p22phox Polymorphisms and Oxidative Stress in Patients With Obstructive Sleep Apnea |
DESIGN: CASE-CONTROL STUDY METHODS: We are going to determine the A-930G and C242T p22phox genotypes in patients with OSA and healthy subjects recruited from sleep unit of Son Dureta University Hospital, (Palma de Mallorca, Spain). 8-Isoprostane is going to be measured as an oxidative stress marker with an 8-isoprostane EIA kit (Cayman Chemicals Company, USA) in plasma samples.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
patients with OSAS defined by an apnea hypopnea index (AHI)>10 h-1 will be included in the study along with control subjects without OSAS. Participants were consequently studied at the sleep unit of Hospital Universitario Son Dureta, (Palma de Mallorca, Spain).
Inclusion Criteria:Polyysomnografic study with Apnoea/Hypoapnoea Index higher to 10 in patients and lower in controls.
Exclusion Criteria:
- chronic obstructive pulmonary disease, liver cirrhosis, thyroid dysfunction, rheumatoid arthritis, chronic renal failure and/or psychiatric disorders.
Contacts and Locations| Contact: Mónica de La Peña, MD | 0034971175112 | monica.delapena@ssib.es |
| Spain | |
| Hospital Universitario Son Dureta | Recruiting |
| Palma de Mallorca, Baleares, Spain, 07014 | |
| Contact: Javier Piérola, Biologist 0034666149639 javier.pierola@ssib.es | |
| Principal Investigator: Javier Piérola, Biologist | |
More Information
No publications provided
| Responsible Party: | Javier Piérola Lopetegui, Hospital Universitario Son Dureta |
| ClinicalTrials.gov Identifier: | NCT01141829 History of Changes |
| Other Study ID Numbers: | NADPHPM2010 |
| Study First Received: | June 10, 2010 |
| Last Updated: | June 10, 2010 |
| Health Authority: | Spain: Ministry of Health and Consumption |
Keywords provided by Sociedad Española de Neumología y Cirugía Torácica:
|
NADPH oxidase |
Additional relevant MeSH terms:
|
Apnea Sleep Apnea Syndromes Sleep Apnea, Obstructive Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory |
Signs and Symptoms Sleep Disorders, Intrinsic Dyssomnias Sleep Disorders Nervous System Diseases |
ClinicalTrials.gov processed this record on June 13, 2013